Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

New Stock Coverage: Can Dick's Sporting Goods Score Big?


Wall Street ratings agencies set the tone for today's stock market.

Today is the anniversary of Wall Street's most famous headline, about its most dire day. That was then, this is now - how things change. (Variety is, after all, the spice of life.) On this October 29, in stark contrast to 1929′s date of infamy, Dow Industrials (INDEXDJX:.DJI) and S&P 500 (INDEXSP:.INX) shares each reached historic peaks. Eighty-four years ago people jumped out of windows; yesterday Omnicom (NYSE:OMC) was inspired by the man who fell to earth, with the advertising giant advancing 0.75% on upbeat analyst comments. Nasdaq (INDEXNASDAQ:.IXIC) hasn't fared quite as well as the other two indices, with five straight increases "only" taking it to a 13-year best. That still wasn't too shabby, considering how it was frozen in time for much of Tuesday. Having exhausted its previous excuses of squirrels and computers, "human error" got the blame this time. And it paid to be spic 'n span, with Clorox (NYSE:CLX), up 1.40%, WD-40 Company (NASDAQ:WDFC), a 2.60% gainer, and Tide maker Procter & Gamble (NYSE:PG), which rose 1.43%, all hitting lifetime highs. Guys, you do really want to start cleaning up.

This afternoon, the Federal Open Market Committee concludes its two-day policy meeting. Hump Day of another busy quarterly earnings week is here, with Allstate (NYSE:ALL), Barclays (NYSE:BCS), Comcast (NASDAQ:CMCSA), Expedia (NASDAQ:EXPE), Facebook (NASDAQ:FB), General Motors (NYSE:GM), Kraft Foods (NASDAQ:KRFT), Metlife (NYSE:MET), Sprint (NYSE:S), Starbucks (NASDAQ:SBUX), and Visa (NYSE:V) all due to release results.

Aegerion Pharmaceuticals (NASDAQ:AEGR): FBR Capital begins the biotech with an Outperform opinion and $105 price objective amid optimism over its Juxtapid launch.

Dick's Sporting Goods (NYSE:DKS): The stock, up 1.31% yesterday, is initiated with a Hold at Jefferies.

Drug Stocks: Alkermes (NASDAQ:ALKS) ($31 target price), Biogen Idec (NASDAQ:BIIB) ($259), and Forest Labs (NYSE:FRX) ($48) are all assigned Market Performs at FBR Capital.

Ecolab (NYSE:ECL): UBS launches Buy-rated research on ECL.

Michael Kors (NYSE:KORS): The fashion firm, about to be added to the S&P 500 Index, is a fresh Buy at Maxim.

Skechers USA (NYSE:SKX): Brean Capital starts the sneaker stock at a Buy.

(See also: Stock Downgrades: US Steel Is No Superman and Stock Upgrades: Electronic Arts Is Out of the Woods)
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos